Alterity Therapeutics (ASX:ATH) appoints new CEO

Company News

by Melissa Darmawan

Alterity Therapeutics (ASX:ATH) has appointed Dr David Stamler as chief executive officer to start today.

Dr Stamler started with the company in 2017 as chief medical officer and senior vice president of clinical development.

The founder of the company, Geoffrey Kempler, will step down as the CEO and continue as non-executive chairman in a consulting capacity.

The succession of Dr David Stamler aligns with the next phase of the company's commercial strategy, which would see the company advance its clinical trials for its lead compound ATH434.

Shares in Alterity Therapeutics (ASX:ATH) are trading 6.5 per cent higher at 3 cents.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.